Search Results

Dilon Technologies Inc. announced today the enrollment of its first patient in the Prospective, Single-Arm, Multi-Center Pivotal Trial for its next generation MarginProbe™ 2 product used in real-time margin assessment.

Dilon Technologies Inc. announced today the publication of Cost Minimization in Breast Conserving Surgery: A Comparative Study of Radiofrequency Spectroscopy and Full Cavity Shave Margins for Patients Undergoing Breast Conserving Surgery, in the Journal of Cost Effectiveness and Resource Allocation.

AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, has signed a multi-year contract with Dilon Technologies, a global leader in devices for breast cancer treatment and diagnosis.

Smart Breast Corporation (SmartBreast™), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain Molecular Breast Imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount. The acquired MBI technology sees through dense breast tissue to fi

The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.

Dilon Technologies® Inc., a world class global leader in breast cancer treatment and diagnosis and owner of the Navigator Gamma Probes has acquired substantially all the assets of Dune Medical, including Dune Medical’s “MarginProbe”.